Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Solid Biosciences (SLDB) Profit After Tax (2017 - 2024)

Solid Biosciences' Profit After Tax history spans 8 years, with the latest figure at -$42.6 million for Q4 2024.

  • For Q4 2024, Profit After Tax fell 109.64% year-over-year to -$42.6 million; the TTM value through Dec 2024 reached -$124.7 million, down 29.9%, while the annual FY2024 figure was -$124.7 million, 29.9% down from the prior year.
  • Profit After Tax for Q4 2024 was -$42.6 million at Solid Biosciences, down from -$32.7 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$15.2 million in Q4 2022 and bottomed at -$42.6 million in Q4 2024.
  • The 5-year median for Profit After Tax is -$21.3 million (2020), against an average of -$23.4 million.
  • The largest annual shift saw Profit After Tax surged 36.69% in 2021 before it crashed 109.64% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$21.4 million in 2020, then grew by 12.89% to -$18.6 million in 2021, then grew by 18.59% to -$15.2 million in 2022, then plummeted by 34.12% to -$20.3 million in 2023, then tumbled by 109.64% to -$42.6 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Profit After Tax are -$42.6 million (Q4 2024), -$32.7 million (Q3 2024), and -$25.1 million (Q2 2024).